Inovio Pharmaceuticals Inc. Begins Rolling Submission of BLA for INO-3107 for RRP Treatment, Aiming for FDA Approval by End of 2025

Reuters

Aug 26

Inovio Pharmaceuticals Inc. Begins Rolling Submission of BLA for INO-3107 for RRP Treatment, Aiming for FDA Approval by End of 2025

INOVIO Pharmaceuticals Inc. has announced that the U.S. Food and Drug Administration (FDA) has agreed to their rolling submission plan for the Biologics License Application (BLA) for INO-3107, a treatment for adults with Recurrent Respiratory Papillomatosis (RRP). The company is on track to complete the submission in the second half of 2025 and aims for file acceptance by the end of the year. INOVIO, which focuses on developing DNA medicines for HPV-related diseases, cancer, and infectious diseases, is leveraging its Breakthrough Therapy designation to expedite discussions with the FDA. This development is seen as a significant step toward providing a new therapeutic option for patients suffering from RRP. There is no mention of grant or funding being obtained by multiple organizations; the announcement pertains solely to INOVIO Pharmaceuticals Inc.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inovio Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH58699) on August 26, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2562735150"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2562735150\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2562735150?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-26 20:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2562735150","market":"nz","top_or_hot":-1,"title":"Inovio Pharmaceuticals Inc. Begins Rolling Submission of BLA for INO-3107 for RRP Treatment, Aiming for FDA Approval by End of 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Inovio Pharmaceuticals Inc. Begins Rolling Submission of BLA for INO-3107 for RRP Treatment, Aiming for FDA Approval by End of 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        INOVIO Pharmaceuticals Inc. has announced that the U.S. Food and Drug Administration (FDA) has agreed to their rolling submission plan for the Biologics License Application (BLA) for INO-3107, a treatment for adults with Recurrent Respiratory Papillomatosis (RRP). The company is on track to complete the submission in the second half of 2025 and aims for file acceptance by the end of the year. INOVIO, which focuses on developing DNA medicines for HPV-related diseases, cancer, and infectious diseases, is leveraging its Breakthrough Therapy designation to expedite discussions with the FDA. This development is seen as a significant step toward providing a new therapeutic option for patients suffering from RRP. There is no mention of grant or funding being obtained by multiple organizations; the announcement pertains solely to INOVIO Pharmaceuticals Inc.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inovio Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH58699) on August 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inovio Pharmaceuticals Inc. Begins Rolling Submission of BLA for INO-3107 for RRP Treatment, Aiming for FDA Approval by End of 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInovio Pharmaceuticals Inc. Begins Rolling Submission of BLA for INO-3107 for RRP Treatment, Aiming for FDA Approval by End of 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-26 20:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Inovio Pharmaceuticals Inc. Begins Rolling Submission of BLA for INO-3107 for RRP Treatment, Aiming for FDA Approval by End of 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        INOVIO Pharmaceuticals Inc. has announced that the U.S. Food and Drug Administration (FDA) has agreed to their rolling submission plan for the Biologics License Application (BLA) for INO-3107, a treatment for adults with Recurrent Respiratory Papillomatosis (RRP). The company is on track to complete the submission in the second half of 2025 and aims for file acceptance by the end of the year. INOVIO, which focuses on developing DNA medicines for HPV-related diseases, cancer, and infectious diseases, is leveraging its Breakthrough Therapy designation to expedite discussions with the FDA. This development is seen as a significant step toward providing a new therapeutic option for patients suffering from RRP. There is no mention of grant or funding being obtained by multiple organizations; the announcement pertains solely to INOVIO Pharmaceuticals Inc.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inovio Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH58699) on August 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INO","symbol_name":"伊诺维奥制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250826:nNDL1hwbl:1","article_id":"2562735150","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2562735150","pubTimestamp":1756209920,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Inovio Pharmaceuticals Inc. Begins Rolling Submission of BLA for INO-3107 for RRP Treatment, Aiming for FDA Approval by End of 2025. INOVIO Pharmaceuticals Inc. has announced that the U.S. Food and Drug Administration  has agreed to their rolling submission plan for the Biologics License Application  for INO-3107, a treatment for adults with Recurrent Respiratory Papillomatosis . The company is on track to complete the submission in the second half of 2025 and aims for file acceptance by the end of the year. INOVIO, which focuses on developing DNA medicines for HPV-related diseases, cancer, and infectious diseases, is leveraging its Breakthrough Therapy designation to expedite discussions with the FDA. This development is seen as a significant step toward providing a new therapeutic option for patients suffering from RRP. There is no mention of grant or funding being obtained by multiple organizations; the announcement pertains solely to INOVIO Pharmaceuticals Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"INO":"伊诺维奥制药","BK4568":"美国抗疫概念","BK4583":"猴痘概念","BK4139":"生物科技"},"translate_title":"Inovio Pharmaceuticals Inc.开始滚动提交INO-3107用于RRP治疗的BLA，目标是在2025年底前获得FDA批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INO":0.9},"content_text":"Inovio Pharmaceuticals Inc. Begins Rolling Submission of BLA for INO-3107 for RRP Treatment, Aiming for FDA Approval by End of 2025\n    \n\n        INOVIO Pharmaceuticals Inc. has announced that the U.S. Food and Drug Administration (FDA) has agreed to their rolling submission plan for the Biologics License Application (BLA) for INO-3107, a treatment for adults with Recurrent Respiratory Papillomatosis (RRP). The company is on track to complete the submission in the second half of 2025 and aims for file acceptance by the end of the year. INOVIO, which focuses on developing DNA medicines for HPV-related diseases, cancer, and infectious diseases, is leveraging its Breakthrough Therapy designation to expedite discussions with the FDA. This development is seen as a significant step toward providing a new therapeutic option for patients suffering from RRP. There is no mention of grant or funding being obtained by multiple organizations; the announcement pertains solely to INOVIO Pharmaceuticals Inc.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inovio Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH58699) on August 26, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}